AbbVie Inc (ABBV)vsGuardian Pharmacy Services, Inc. (GRDN)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
GRDN
Guardian Pharmacy Services, Inc.
$37.10
-1.25%
HEALTHCARE · Cap: $2.42B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4122% more annual revenue ($61.16B vs $1.45B). ABBV leads profitability with a 6.9% profit margin vs 3.4%. GRDN trades at a lower P/E of 48.2x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
GRDN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+79.3%
Fair Value
$166.71
Current Price
$37.10
$129.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 27 in profit
17.4% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 11.4x book value
0.0% earnings growth
3.4% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : GRDN
The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : GRDN
The primary concerns for GRDN are Price/Book, EPS Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while GRDN is a growth play — different risk/reward profiles.
GRDN is growing revenue faster at 17.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 46/100). GRDN offers better value entry with a 79.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Guardian Pharmacy Services, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Guardian Pharmacy Services, Inc. is a premier provider of specialized pharmacy solutions tailor-made for the long-term care sector, encompassing assisted living and skilled nursing facilities. The company distinguishes itself through a commitment to personalized medication management, rigorous standards of quality and compliance, and exceptional customer service. By leveraging state-of-the-art technology and extensive pharmaceutical expertise, Guardian enhances patient outcomes while optimizing workflows for healthcare partners. With a robust operational footprint across multiple states, the company is strategically positioned to meet the increasing demand for customized pharmacy services in a dynamic healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?